- Home
- CIIT vs PULM Comparison
CIIT vs PULM Comparison
Compare CIIT & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIIT
- PULM
- Stock Information
- Founded
- CIIT N/A
- PULM 2003
- Country
- CIIT Hong Kong
- PULM United States
- Employees
- CIIT N/A
- PULM N/A
- Industry
- CIIT
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- CIIT
- PULM Health Care
- Exchange
- CIIT NYSE
- PULM Nasdaq
- Market Cap
- CIIT 36.0M
- PULM 33.2M
- IPO Year
- CIIT N/A
- PULM N/A
- Fundamental
- Price
- CIIT $1.08
- PULM $6.08
- Analyst Decision
- CIIT
- PULM
- Analyst Count
- CIIT 0
- PULM 0
- Target Price
- CIIT N/A
- PULM N/A
- AVG Volume (30 Days)
- CIIT 267.1K
- PULM 50.1K
- Earning Date
- CIIT 06-09-2025
- PULM 08-12-2025
- Dividend Yield
- CIIT N/A
- PULM N/A
- EPS Growth
- CIIT N/A
- PULM N/A
- EPS
- CIIT N/A
- PULM N/A
- Revenue
- CIIT $9,464,501.00
- PULM $1,921,000.00
- Revenue This Year
- CIIT N/A
- PULM N/A
- Revenue Next Year
- CIIT N/A
- PULM $134.88
- P/E Ratio
- CIIT N/A
- PULM N/A
- Revenue Growth
- CIIT 51.52
- PULM N/A
- 52 Week Low
- CIIT $0.56
- PULM $1.78
- 52 Week High
- CIIT $5.38
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- CIIT N/A
- PULM 38.77
- Support Level
- CIIT N/A
- PULM $6.07
- Resistance Level
- CIIT N/A
- PULM $6.49
- Average True Range (ATR)
- CIIT 0.00
- PULM 0.31
- MACD
- CIIT 0.00
- PULM -0.03
- Stochastic Oscillator
- CIIT 0.00
- PULM 6.63
About CIIT TIANCI INTERNATIONAL INC
Tianci International Inc along with its subsidiaries is engaged in sale of components of electronic devices, development of software and websites, technical consulting, and providing maintenance support on customized software. The company's business is predominantly carried out in Hong Kong with a substantial portion of its overall revenue being generated from its Electronic Device Hardware Components Sales segment.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).